Accessibility Menu

Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.

By Todd Campbell Sep 15, 2020 at 1:31PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.